allergic rhinoconjunctivitis (hayfever)

From Aaushi
Jump to navigation Jump to search
[1][2][3][4][5][6][7][8][9][10][11][12][13][14]

Etiology

Pathology

Genetics

Clinical manifestations

Laboratory

Radiology

Complications

Differential diagnosis

Management

More general terms

Additional terms

References

  1. ↑ Saunders Manual of Medical Practice, Rakel (ed), WB Saunders, Philadelphia, 1996, pg 84-86
  2. ↑ Medical Knowledge Self Assessment Program (MKSAP) 11, American College of Physicians, Philadelphia 1998
  3. ↑ 3.0 3.1 Journal Watch 22(9):70, 2002 Rinne et al, Clin Immunol 109:426, 2002
  4. ↑ Singulair (Montelukast) for Seasonal Allergic Rhinitis Prescriber's Letter 10(2):9 2003 Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=190210&pb=PRL (subscription needed) http://www.prescribersletter.com
  5. ↑ Meltzer EO. Evaluation of the optimal oral antihistamine for patients with allergic rhinitis. Mayo Clin Proc. 2005 Sep;80(9):1170-6. PMID: https://www.ncbi.nlm.nih.gov/pubmed/16178497
  6. ↑ Prescriber's Letter 13(4): 2006 Drug Treatments for Allergic Rhinitis Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=220414&pb=PRL (subscription needed) http://www.prescribersletter.com
  7. ↑ Prescriber's Letter 14(1): 2007 Ophthalmic Medications for Allergic Conjunctivitis Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=230106&pb=PRL (subscription needed) http://www.prescribersletter.com
  8. ↑ Wahn U et al Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. J Allergy Clin Immunol 2009 Jan; 123:160 PMID: https://www.ncbi.nlm.nih.gov/pubmed/19046761
    Bufe A et al Safety and efficacy in children of an SQ-standardized grass allergen table for sublingual immunotherapy. J Allergy Clin Immunol 2009 Jan; 123:167. PMID: https://www.ncbi.nlm.nih.gov/pubmed/19130937
    Frew AJ. Sublingual immunotherapy. N Engl J Med. 2008 May 22;358(21):2259-64. Review. PMID: https://www.ncbi.nlm.nih.gov/pubmed/18499568
  9. ↑ Prescriber's Letter 16(8): 2009 COMMENTARY: Neuropsychiatric Adverse Effects with Leukotriene Modifiers GUIDELINES: NAEPP Guidelines for the Diagnosis and Management of Asthma - Summary Report 2007 GUIDELINES: The Diagnosis and Management of Rhinitis: An Updated Practice Parameter Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=250805&pb=PRL
  10. ↑ 10.0 10.1 Medical Knowledge Self Assessment Program (MKSAP) 14, 15, American College of Physicians, Philadelphia 2006, 2009
  11. ↑ 11.0 11.1 Durham SR et al. Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet. J Allergy Clin Immunol 2010 Jan; 125:131 PMID: https://www.ncbi.nlm.nih.gov/pubmed/20109743
  12. ↑ 12.0 12.1 Prenner BM et al. Mometasone furoate nasal spray reduces the ocular symptoms of seasonal allergic rhinitis. J Allergy Clin Immunol 2010 Jun; 125:1247 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/20434199 <Internet> http://dx.doi.org/10.1016/j.jaci.2010.03.004
  13. ↑ Baroody FM et al. Oxymetazoline adds to the effectiveness of fluticasone furoate in the treatment of perennial allergic rhinitis. J Allergy Clin Immunol 2011 Apr; 127:927. PMID: https://www.ncbi.nlm.nih.gov/pubmed/21377716
  14. ↑ 14.0 14.1 Didier A et al. Sustained 3-year efficacy of pre- and coseasonal 5-grass- pollen sublingual immunotherapy tablets in patients with grass pollen-induced rhinoconjunctivitis. J Allergy Clin Immunol 2011 Sep; 128:559 PMID: https://www.ncbi.nlm.nih.gov/pubmed/21802126
Retrieved from "https://aaushi.info/w/index.php?title=A32520&oldid=1207508"